Maria Santoro

Fonte dei dati: Archivio della Ricerca
  1. Lombardi, F., Giacomelli, A., Armenia, D., Lai, A., Dusina, A., Bezench, A., et al. (2021). Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 57(2) [10.1016/j.ijantimicag.2020.106252]. Dettagli
  2. Santoro, M., Fornabaio, C., Malena, M., Galli, L., Poli, A., Menozzi, M., et al. (2020). Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 56(1) [10.1016/j.ijantimicag.2020.106027]. Dettagli
  3. Bouba, Y., Berno, G., Fabeni, L., Carioti, L., Salpini, R., Aquaro, S., et al. (2020). Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(7), 1778-1786 [10.1093/jac/dkaa073]. Dettagli
  4. Armenia, D., Di Carlo, D., Flandre, P., Bouba, Y., Borghi, V., Forbici, F., et al. (2020). HIV MDR is still a relevant issue despite its dramatic drop over the years. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(5), 1301-1310 [10.1093/jac/dkz554]. Dettagli
  5. Soulie, C., Santoro, M.M., Storto, A., Abdi, B., Charpentier, C., Armenia, D., et al. (2020). Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkz553]. Dettagli
  6. Alteri, C., Scutari, R., Stingone, C., Maffongelli, G., Brugneti, M., Falasca, F., et al. (2019). Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. JOURNAL OF CLINICAL VIROLOGY, 117, 61-67. Dettagli
  7. Fabeni, L., Alteri, C., Berno, G., Scutari, R., Orchi, N., De Carli, G., et al. (2019). Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. SEXUALLY TRANSMITTED INFECTIONS, 95(8), 619-625. Dettagli
  8. Armenia, D., Di Carlo, D., Cozzi-Lepri, A., Calcagno, A., Borghi, V., Gori, C., et al. (2019). Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. ANTIVIRAL THERAPY, 24(5), 321-331. Dettagli
  9. Antinori, A., Santoro, M.m., Gagliardini, R., Marchetti, G., Mondi, A., Cento, V., et al. (2019). Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. NEW MICROBIOLOGICA, 42(2), 69-80. Dettagli
  10. Alteri, C., Scutari, R., Bertoli, A., Armenia, D., Gori, C., Fabbri, G., et al. (2019). Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. VIRUS GENES [10.1007/s11262-019-01649-z]. Dettagli
  11. Fokam, J., Sosso, S.M., Yagai, B., Billong, S.C., Djubgang Mbadie, R.E., Kamgaing Simo, R., et al. (2019). Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: Adolescents at high risk of virological failure in the era of "test and treat". AIDS RESEARCH AND THERAPY, 16(1), 36 [10.1186/s12981-019-0252-0]. Dettagli
  12. Pouga, L., Santoro, M.m., Charpentier, C., Di Carlo, D., Romeo, I., Artese, A., et al. (2019). New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). CHEMICAL BIOLOGY & DRUG DESIGN, 93(1), 50-59 [10.1111/cbdd.13378]. Dettagli
  13. Rusconi, S., Santoro, M.m., Gianotti, N., Antinori, A., Bonora, S., Cingolani, A., et al. (2019). Is the rate of virological failure to cART continuing to decline in recent calendar years?. JOURNAL OF CLINICAL VIROLOGY, 116, 23-28 [10.1016/j.jcv.2019.04.009]. Dettagli
  14. Takou, D., Fokam, J., Teto, G., Santoro, M.-., Ceccherini-Silberstein, F., Nanfack, A.J., et al. (2019). HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon. BMC INFECTIOUS DISEASES, 19(1), 246 [10.1186/s12879-019-3871-0]. Dettagli
  15. Alteri, C., Fabeni, L., Scutari, R., Berno, G., Di Carlo, D., Gori, C., et al. (2018). Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence. SCIENTIFIC REPORTS, 8(1), 15739. Dettagli
  16. Raffaelli, C.S., Rossetti, B., Paglicci, L., Colafigli, M., Punzi, G., Borghi, V., et al. (2018). Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(9), 2480-2484 [10.1093/jac/dky211]. Dettagli
  17. Armenia, D., Zaccarelli, M., Borghi, V., Gennari, W., Di Carlo, D., Giannetti, A., et al. (2018). Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. JOURNAL OF CLINICAL VIROLOGY, 104, 61-64. Dettagli
  18. Fokam, J., Bellocchi, M.c., Armenia, D., Nanfack, A.j., Carioti, L., Continenza, F., et al. (2018). Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children. MEDICINE, 97(13), e0176 [10.1097/MD.0000000000010176]. Dettagli
  19. Santoro, M., Di Carlo, D., Armenia, D., Zaccarelli, M., Pinnetti, C., Colafigli, M., et al. (2018). Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. ANTIVIRAL THERAPY, 23(3), 249-257 [10.3851/IMP3197]. Dettagli
  20. Fabeni, L., Berno, G., Fokam, J., Bertoli, A., Alteri, C., Gori, C., et al. (2017). Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains. JOURNAL OF CLINICAL MICROBIOLOGY, JCM.00656-17 [10.1128/JCM.00656-17]. Dettagli
  21. Armenia, D., Di Carlo, D., Maffongelli, G., Borghi, V., Alteri, C., Forbici, F., et al. (2017). Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens. HIV MEDICINE [10.1111/hiv.12388]. Dettagli
  22. Fabeni, L., Alteri, C., Di Carlo, D., Orchi, N., Carioti, L., Bertoli, A., et al. (2017). Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(10), 2837-2845 [10.1093/jac/dkx231]. Dettagli
  23. Rhee, S.-., Varghese, V., Holmes, S.P., Van Zyl, G.U., Steegen, K., Boyd, M.A., et al. (2017). Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBIOMEDICINE, 18, 225-235 [10.1016/j.ebiom.2017.03.024]. Dettagli
  24. Nanfack, A.J., Takou, D., Fokam, J., Salpini, R., Santoro, M.M., Cappelli, G., et al. (2016). HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design. CURRENT HIV RESEARCH, 15(1), 66-73 [10.2174/1570162X14666161230105417]. Dettagli
  25. Armenia, D., Di Carlo, D., Calcagno, A., Vendemiati, G., Forbici, F., Bertoli, A., et al. (2016). Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, dkw512 [10.1093/jac/dkw512]. Dettagli
  26. Alteri, C., Surdo, M., Di Maio, V., Di Santo, F., Costa, G., Parrotta, L., et al. (2016). The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate + emtricitabine-containing HAART both in vivo and in vitro. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 7, 1-7 [10.1016/j.jgar.2016.06.005]. Dettagli
  27. De Luca, A., Flandre, P., Dunn, D., Zazzi, M., Wensing, A., Santoro, M.m., et al. (2016). Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(5), 1352-1360 [10.1093/jac/dkv465]. Dettagli
  28. Gregson, J., Tang, M., Ndembi, N., Hamers, R.L., Marconi, V.C., Brooks, K., et al. (2016). Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study. THE LANCET INFECTIOUS DISEASES, 16(5), 565-575 [10.1016/S1473-3099(15)00536-8]. Dettagli
  29. Santoro, M.M., & Perno, C.F. (2016). Clinical relevance of genotypic resistance testing today. NEW MICROBIOLOGICA, 39(2), 91-92. Dettagli
  30. Di Maio, V., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., et al. (2016). HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(3), 739-750 [10.1093/jac/dkv403]. Dettagli
  31. Fokam, J., Takou, D., Santoro, M., Akonie, H., Kouanfack, C., Ceccherini Silberstein, F., et al. (2016). Short communication: Population-based surveillance of HIV-1 drug resistance in cameroonian adults initiating antiretroviral therapy according to the world health organization guidelines. AIDS RESEARCH AND HUMAN RETROVIRUSES, 32(4), 329-333 [10.1089/AID.2015.0065]. Dettagli
  32. Maffongelli, G., Alterib, C., Gentilotti, E., Bertoli, A., Ricciardi, A., Malagnino, V., et al. (2016). Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy. AIDS [10.1097/QAD.0000000000000977]. Dettagli
  33. Salpini, R., Fokam, J., Ceccarelli, L., Santoro, M., Nanfack, A., Sosso, S., et al. (2016). High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians. CURRENT HIV RESEARCH, 14(2), 165-171 [10.2174/1570162X13666150930114742]. Dettagli
  34. Zaccarelli, M., Santoro, M.m., Armenia, D., Borghi, V., Gennari, W., Gori, C., et al. (2016). Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. JOURNAL OF CLINICAL VIROLOGY, 82, 94-100 [10.1016/j.jcv.2016.07.007]. Dettagli
  35. Andreoni, M., Marcotullio, S., Puro, V., De Carli, G., Tambussi, G., Nozza, S., et al. (2015). An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. NEW MICROBIOLOGICA, 38(4), 443-490. Dettagli
  36. Fabeni, L., Berno, G., Svicher, V., Ceccherini-Silberstein, F., Gori, C., Bertoli, A., et al. (2015). Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia. JOURNAL OF CLINICAL MICROBIOLOGY, 53(9), 2935-2941 [10.1128/JCM.00893-15]. Dettagli
  37. Vingerhoets, J., Calvez, V., Flandre, P., Marcelin, A.-., Ceccherini Silberstein, F., Perno, C.F., et al. (2015). Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data. HIV MEDICINE, 16(5), 297-306 [10.1111/hiv.12218]. Dettagli
  38. Armenia, D., Fabeni, L., Alteri, C., Di Pinto, D., Di Carlo, D., Bertoli, A., et al. (2015). HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1865-1873 [10.1093/jac/dkv029]. Dettagli
  39. Fabeni, L., Alteri, C., Orchi, N., Gori, C., Bertoli, A., Forbici, F., et al. (2015). Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy. PLOS ONE, 10(8), e0135325 [10.1371/journal.pone.0135325]. Dettagli
  40. Blanco, J.l., Montaner, J., Marconi, V.c., Santoro, M.m., Campos-Loza, A.e., Shafer, R.w., et al. (2014). Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovirRemtricitabine/lamivudineRefavirenz administered on a multiple tablet therapy. AIDS, 28(17), 2531-2539 [10.1097/QAD.0000000000000424]. Dettagli
  41. Mirabelli, C., Surdo, M., Van Hemert, F., Lian, Z., Salpini, R., Cento, V., et al. (2014). Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection. JOURNAL OF INFECTION [10.1016/j.jinf.2014.10.015]. Dettagli
  42. Armenia, D., Soulie, C., Di Carlo, D., Fabeni, L., Gori, C., Forbici, F., et al. (2014). A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. PLOS ONE, 9(8) [10.1371/journal.pone.0105853]. Dettagli
  43. Svicher, V., Alteri, C., Santoro, M., Ceccherini-Silberstein, F., Marcelin, A., Calvez, V., et al. (2014). The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature. JOURNAL OF INFECTION [10.1016/j.jinf.2014.05.001]. Dettagli
  44. Santoro, M., Fabeni, L., Armenia, D., Alteri, C., Di Pinto, D., Forbici, F., et al. (2014). Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. CLINICAL INFECTIOUS DISEASES, 58(8), 1156-1164 [10.1093/cid/ciu020]. Dettagli
  45. Santoro, M., Sabin, C., Forbici, F., Bansi, L., Dunn, D., Fearnhill, E., et al. (2013). Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV MEDICINE, 841-845 [10.1111/hiv.12044]. Dettagli
  46. Alteri, C., Artese, A., Beheydt, G., Santoro, M., Costa, G., Parrotta, L., et al. (2013). Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(10), 2205-2209 [10.1093/jac/dkt173]. Dettagli
  47. Santoro, M., Armenia, D., Alteri, C., Flandre, P., Calcagno, A., Santoro, M., et al. (2013). Impact of pre-therapy viral load on virological response to modern first-line HAART. ANTIVIRAL THERAPY, 18(7), 867-876 [10.3851/IMP2531]. Dettagli
  48. Giuliani, M., Santoro, M., Lo Presti, A., Cella, E., Scognamiglio, P., Lai, A., et al. (2013). Circulation of HIV-1 CRF02_AG among MSM population in central Italy: a molecular epidemiology-based study. BIOMED RESEARCH INTERNATIONAL, 2013, 810617-810617. Dettagli
  49. Santoro, M., & Perno, C. (2013). HIV-1 Genetic Variability and Clinical Implications. ISRN MICROBIOLOGY, 2013, 481314-481314. Dettagli
  50. Svicher, V., Cento, V., Rozera, G., Abbate, I., Santoro, M., Armenia, D., et al. (2013). The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLOS ONE, 8(1) [10.1371/journal.pone.0053603]. Dettagli
  51. Ciccozzi, M., Santoro, M., Giovanetti, M., Andrissi, L., Bertoli, A., & Ciotti, M. (2012). HIV-1 non-B subtypes in Italy: a growing trend. NEW MICROBIOLOGICA, 35(4), 377-386. Dettagli
  52. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2012). The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. CLINICAL MICROBIOLOGY AND INFECTION, 18(8) [10.1111/j.1469-0691.2012.03905.x]. Dettagli
  53. Ceccarelli, L., Salpini, R., Moudourou, S., Cento, V., Santoro, M., Fokam, J., et al. (2012). Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon. JOURNAL OF MEDICAL VIROLOGY, 84(5), 721-727 [10.1002/jmv.23244]. Dettagli
  54. Santoro, M.M., Alteri, C., Ronga, L., Flandre, P., Fabeni, L., Mercurio, F., et al. (2012). Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 28(10), 1285-1293 [10.1089/aid.2011.0142]. Dettagli
  55. Alcaro, S., Alteri, C., Artese, A., Ceccherini-Silberstein, F., Costa, G., Ortuso, F., et al. (2011). Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine. CHEMMEDCHEM, 6(12), 2203-2213 [10.1002/cmdc.201100362]. Dettagli
  56. Alteri, C., Santoro, M.M., Abbate, I., Rozera, G., Bruselles, A., Bartolini, B., et al. (2011). 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [10.1093/jac/dkr354]. Dettagli
  57. Alteri, C., Santoro, M.M., Abbate, I., Rozera, G., Bruselles, A., Bartolini, B., et al. (2011). 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY [doi: 10.1093/jac/dkr354]. Dettagli
  58. Fokam, J., Salpini, R., Santoro, M.M., Cento, V., Perno, C., Colizzi, V., et al. (2011). Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL [10.1097/INF.0b013e31822db54c]. Dettagli
  59. Ciccozzi, M., Vujošević, D., Lo Presti, A., Mugoša, B., Vratnica, Z., Lai, A., et al. (2011). Genetic diversity of HIV type 1 in Montenegro. AIDS RESEARCH AND HUMAN RETROVIRUSES, 27(8), 921-924 [10.1089/AID.2010.0323]. Dettagli
  60. Véras, N., Santoro, M.M., Gray, R.R., Tatem, A.J., Presti, A.L., Olearo, F., et al. (2011). Molecular Epidemiology of HIV Type 1 CRF02_AG in Cameroon and African Patients Living in Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES. Dettagli
  61. Fokam, J., Salpini, R., Santoro, M.M., Cento, V., D'Arrigo, R., Gori, C., et al. (2011). Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. ARCHIVES OF VIROLOGY, 156(7), 1235-1243. Dettagli
  62. Ceccherini-Silberstein, F., Surdo, M., Alteri, C., Puertas, M.C., Saccomandi, P., Artese, A., et al. (2011). HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029. Paper presented at International Workshop on HIV & Hepatitis virus Drug Resistance and curative strategies, Los Cabos, Mexico. Dettagli
  63. Cento, V., Svicher, V., Rozera, G., Abbate, I., Santoro, M., Armenia, D., et al. (2011). The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  64. De Luca, A., Di Giambenedetto, S., Maserati, R., Gianotti, N., Narciso, P., Antinori, A., et al. (2011). Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. ANTIVIRAL THERAPY, 16(4), 489-497 [10.3851/IMP1799]. Dettagli
  65. Santoro, M., Armenia, D., Fabeni, L., Santoro, M., Gori, C., Forbici, F., et al. (2011). The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion. Paper presented at 3th ICAR – Italian Conference on AIDS and Retroviruses, Firenze, Italia. Dettagli
  66. Svicher, V., Alteri, C., Artese, A., Forbici, F., Santoro, M.M., Schols, D., et al. (2010). Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 336-344 [10.1097/QAI.0b013e3181e6763f]. Dettagli
  67. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, et al. (2010). Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 336-344 [doi: 10.1097/QAI.0b013e3181e6763f]. Dettagli
  68. Zehender, G., Ebranati, E., Lai, A., Santoro, M.M., Alteri, C., Giuliani, M., et al. (2010). Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(2), 156-160. Dettagli
  69. Tommasi, C., Ceccherini-Silberstein, F., D'Arrigo, R., Bellagamba, R., Tempestilli, M., Dessì, C., et al. (2010). Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 42(3), 237-239. Dettagli
  70. Zaccarelli, M., Antinori, A., Cozzi-Lepri, A., Mussini, C., Palamara, G., Santoro, M.M., et al. (2010). Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 53(1), 150-151. Dettagli
  71. Schapiro, J.M., Scherer, J., Boucher, C.A., Baxter, J.D., Tilke, C., Perno, C.F., et al. (2010). Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. ANTIVIRAL THERAPY, 15(7), 1011-1019. Dettagli
  72. Santoro, M., Bertoli, A., Lorenzini, P., Ceccherini-Silberstein, F., Gianotti, N., Mussini, C., et al. (2009). Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients. INFECTION, 37(3), 233-243 [10.1007/s15010-008-8065-4]. Dettagli
  73. Giuliani, M., Montieri, S., Palamara, G., Latini, A., Alteri, C., Perno CF, et al. (2009). Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 25(2), 157-164. Dettagli
  74. Trignetti, M., Sing, T., Svicher, V., Santoro, M., Forbici, F., D'arrigo, R., et al. (2009). Dynamics of NRTI resistance mutations during therapy interruption. AIDS RESEARCH AND HUMAN RETROVIRUSES, 25(1), 57-64 [10.1089/aid.2008.0159]. Dettagli
  75. Santoro, M., Ciccozzi, M., Alteri, C., Montieri, S., Alexiev, I., Dimova, I., et al. (2008). Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria. AIDS RESEARCH AND HUMAN RETROVIRUSES, 24(9), 1133-1138. Dettagli
  76. Svicher, V., Aquaro, S., D'Arrigo, R., Artese, A., Dimonte, S., Alcaro, S., et al. (2008). Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. THE JOURNAL OF INFECTIOUS DISEASES, 197(10), 1408-1418 [10.1086/587693]. Dettagli
  77. Santoro, M., Bertoli, A., Lorenzini, P., Lazzarin, A., Esposito, R., Carosi, G., et al. (2008). Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS PATIENT CARE AND STDS, 22(1), 7-16 [10.1089/apc.2007.0013]. Dettagli
  78. Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M., Forbici, F., et al. (2007). Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. JOURNAL OF VIROLOGY, 81(20), 11507-11519 [10.1128/JVI.00303-07]. Dettagli
  79. Aquaro, S., D'Arrigo, R., Svicher, V., Perri, G., Caputo, S., Visco-Comandini, U., et al. (2006). Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(4), 714-722 [10.1093/jac/dkl306]. Dettagli
  80. Svicher, V., Sing, T., Santoro, M., Forbici, F., Rodríguez-Barrios, F., Bertoli, A., et al. (2006). Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. JOURNAL OF VIROLOGY, 80(14), 7186-7198 [10.1128/JVI.02084-05]. Dettagli
  81. Santoro, M., Svicher, V., Gori, C., Zaccarelli, M., Tozzi, V., Forbici, F., et al. (2006). Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy. NEW MICROBIOLOGICA, 29(2), 89-100. Dettagli
  82. Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodríguez-Barrios, F., et al. (2005). High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. JOURNAL OF VIROLOGY, 79(16), 10718-10729 [10.1128/JVI.79.16.10718-10729.2005]. Dettagli
  83. Santoro, M., Ceccherini-Silberstein, F., Gori, C., Svicher, V., Forbici, F., Bellocchi, M., et al. (2004). Temporal change in the use of genotypic resistance testing over the years 1999--2003. NEW MICROBIOLOGICA, 27(2 Suppl 1), 141-144. Dettagli
  84. Buschini, A., Martino, A., Gustavino, B., Monfrinotti, M., Poli, P., Rossi, C., et al. (2004). Comet assay and micronucleus test in circulating erythrocytes of Cyprinus carpio specimens exposed in situ to lake waters treated with disinfectants for potabilization. MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 557, 119-129. Dettagli